iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Last trade$90.98
Day change+$0.15 (+0.17%)
Day range$88.79 – $92.11
Volume235,800
Market cap$3.05B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.05B
Price / earnings
—
Price / book
17.24×
Price / sales
3.58×
EV / sales
3.88×
EV / EBITDA
82.92×
Profitability
Earnings per share
-$1.15
Return on assets
-3.54%
Return on equity
-21.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.68×
Current ratio
3.57×
Quick ratio
3.45×
Cash ratio
1.93×
Cash flow
Price / cash flow
54.96×
Price / free cash flow
413.7×
Free cash flow
$7.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IRTC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$221.59M
$224.17M
$199.39M
$208.89M
$192.88M
$186.69M
$158.68M
$164.33M
Cost of revenue
$57.1M
$60.97M
$58.04M
$60.84M
$55.76M
$53.83M
$49.46M
$49.26M
Gross profit
$164.49M
$163.21M
$141.35M
$148.06M
$137.12M
$132.86M
$109.22M
$115.07M
Selling, general and administrative
$125.64M
$131.66M
$135.88M
$122M
$124.22M
$126.38M
$119.96M
$99.77M
Research and development
$20.6M
$19.84M
$21.36M
$21.05M
$21.03M
$21.01M
$21.52M
$19.08M
Total operating expenses
$197.05M
$165.75M
$157.54M
$145.77M
$145.55M
$151.57M
$141.77M
$119.15M
Operating income
-$32.56M
-$2.54M
-$16.19M
$2.29M
-$8.43M
-$18.71M
-$32.56M
-$4.08M
Interest expense
-$3.3M
-$3.29M
-$3.29M
-$3.32M
-$3.28M
-$3.28M
-$3.27M
-$3.32M
Income before taxes
-$29.85M
-$381K
-$13.43M
$6.03M
-$5.19M
-$14.4M
-$30.04M
-$1.18M
Income taxes
$0
$0
$500K
$447K
$24K
-$183K
$665K
$151K
Net income
-$29.85M
-$381K
-$13.93M
$5.58M
-$5.21M
-$14.22M
-$30.7M
-$1.33M
Net income attributable to common shareholders
-$29.85M
-$381K
-$13.93M
$5.58M
-$5.21M
-$14.22M
-$30.7M
-$1.33M
EBITDA
$23.58M
$16.93M
-$10.85M
$10.26M
-$2.95M
-$9.43M
-$27.05M
$1.51M
Basic earnings per share
-$0.90
-$0.01
-$0.43
$0.17
-$0.16
-$0.44
-$0.97
-$0.04
Diluted earnings per share
-$0.90
-$0.01
-$0.43
$0.17
-$0.16
-$0.44
-$0.97
-$0.04
Recent news
Company coverage with links to the original publishers.
iRhythm Holdings (IRTC) reported Q3 2026 earnings of $0.82 per share, significantly beating the consensus estimate of $0.02, representing a 4,000% surprise. However, revenues of $221.59 million slightly missed expectations by 0.31%. Despite the earnings beat, the stock has underperformed the market by 24.5% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.
Tempus AI demonstrated improving operating leverage in Q2 2026 with 22% revenue growth to $382.5M and adjusted EBITDA reaching $8M (a $13.6M improvement). The company completed a $460M convertible notes offering expected to reduce annual interest expenses by over $30M. Tempus raised its 2026 revenue guidance to $1.595-$1.605B while maintaining adjusted EBITDA guidance of $65M, supporting its goal of achieving positive free cash flow by year-end 2026.
Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%. However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.
Edelson Lechtzin LLP is investigating a data breach at the Shipping Association of New York and New Jersey after unauthorized access on May 27, 2026 exposed personal information of benefit plan participants. The Qilin ransomware group claimed responsibility for the theft. Affected data may include names, Social Security numbers, driver's license numbers, and medical information. The law firm is offering free case evaluations for potential class action claims.
iRhythm Holdings, a San Francisco-based heart-monitoring company, suffered a data breach in June 2026 affecting approximately 8 million patients. Unauthorized access to third-party business applications exposed sensitive patient information including names, contact details, insurance numbers, and device serial numbers. The company disclosed the incident to the SEC and began notifying affected individuals in October 2026. A national class action law firm is investigating potential claims for compensation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.